Drug intelligence / Profile preview

YN209

Development stage: Preclinical
Lead developer: Innogen

Overview

YN209 is an investigational drug candidate currently in the preclinical stage of development by Guangzhou Yinnuo Pharmaceutical (also known as Innogen). It is being developed for the treatment of metabolic-associated steatohepatitis (MASH). While Guangzhou Yinnuo Pharmaceutical's lead assets, such as esupasemide α, focus on glucagon-like peptide-1 receptor (GLP-1R) agonism for metabolic disorders, the specific molecular target and modality for YN209 have not yet been publicly disclosed by the company.

Beyond the preview

Go deeper on YN209.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YN209.

Explore the full profile